Clinical characteristics of the cHL series
| Characteristic . | Estimation, n (%) . | Validation, n (%) . | Total, n (%) . | P . |
|---|---|---|---|---|
| Age, y | (n = 183) | (n = 79) | (n = 262) | |
| Younger than 45 | 133 (72.67) | 56 (70.88) | 189 (72.14) | .883 |
| 45 or older | 50 (27.32) | 23 (29.11) | 73 (27.86) | |
| Sex | (n = 183) | (n = 79) | (n = 262) | |
| Male | 99 (54.10) | 51 (64.55) | 150 (57.25) | .151 |
| Female | 84 (45.90) | 28 (35.44) | 112 (42.75) | |
| Stage IV | (n = 182) | (n = 79) | (n = 261) | |
| No | 132 (72.52) | 47 (59.49) | 179 | .053 |
| Yes | 50 (37.87) | 32 (40.50) | 82 | |
| IPS code | (n = 182) | (n = 79) | (n = 261) | |
| Less than 3 | 109 (59.89) | 41 (51.90) | 150 (57.47) | .288 |
| 3 or greater | 73 (40.11) | 38 (48.10) | 111 | |
| Outcome | (n = 183) | (n = 79) | (n = 262) | |
| F | 132 (72.14) | 57 (72.16) | 189 (72.14) | > .999 |
| U | 51 (27.86) | 22 (27.84) | 73 (27.86) |
| Characteristic . | Estimation, n (%) . | Validation, n (%) . | Total, n (%) . | P . |
|---|---|---|---|---|
| Age, y | (n = 183) | (n = 79) | (n = 262) | |
| Younger than 45 | 133 (72.67) | 56 (70.88) | 189 (72.14) | .883 |
| 45 or older | 50 (27.32) | 23 (29.11) | 73 (27.86) | |
| Sex | (n = 183) | (n = 79) | (n = 262) | |
| Male | 99 (54.10) | 51 (64.55) | 150 (57.25) | .151 |
| Female | 84 (45.90) | 28 (35.44) | 112 (42.75) | |
| Stage IV | (n = 182) | (n = 79) | (n = 261) | |
| No | 132 (72.52) | 47 (59.49) | 179 | .053 |
| Yes | 50 (37.87) | 32 (40.50) | 82 | |
| IPS code | (n = 182) | (n = 79) | (n = 261) | |
| Less than 3 | 109 (59.89) | 41 (51.90) | 150 (57.47) | .288 |
| 3 or greater | 73 (40.11) | 38 (48.10) | 111 | |
| Outcome | (n = 183) | (n = 79) | (n = 262) | |
| F | 132 (72.14) | 57 (72.16) | 189 (72.14) | > .999 |
| U | 51 (27.86) | 22 (27.84) | 73 (27.86) |
Clinical characteristics of patients with adequate RT-PCR profiles. Summary of the clinical characteristics of the patients in the estimation and validation sets that yielded suitable analyzable data (262 of 282; 92.90%). Differences in distribution of standard clinical parameters (age, sex, stage, IPS and outcome) between estimation and validation datasets tested by Pearson chi-square with Yates correction were not statistically significant (IPS values of 0-2 classified as low IPS; IPS values > 2 classified as high IPS).
cHL indicates classical Hodgkin lymphoma; F, favorable response; IPS, International Prognostic Score; RT-PCR, reverse transcription polymerase chain reaction; U, unfavorable response.